Weaver Capital Management LLC Grows Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Weaver Capital Management LLC grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 20.1% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,764 shares of the medical equipment provider’s stock after acquiring an additional 295 shares during the period. Weaver Capital Management LLC’s holdings in Intuitive Surgical were worth $785,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of ISRG. Indiana Trust & Investment Management CO lifted its position in Intuitive Surgical by 5.3% in the second quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after purchasing an additional 25 shares during the last quarter. Hoxton Planning & Management LLC increased its stake in shares of Intuitive Surgical by 4.9% during the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 25 shares during the period. First Affirmative Financial Network increased its stake in shares of Intuitive Surgical by 2.7% during the second quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock valued at $443,000 after buying an additional 26 shares during the period. Advance Capital Management Inc. increased its stake in shares of Intuitive Surgical by 3.8% during the first quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock valued at $295,000 after buying an additional 27 shares during the period. Finally, Perigon Wealth Management LLC increased its stake in shares of Intuitive Surgical by 0.5% during the first quarter. Perigon Wealth Management LLC now owns 5,363 shares of the medical equipment provider’s stock valued at $2,140,000 after buying an additional 27 shares during the period. Institutional investors own 83.64% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on ISRG. JPMorgan Chase & Co. upped their price target on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Robert W. Baird upped their price target on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. Piper Sandler upped their price target on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. BTIG Research upped their price target on Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Finally, Stifel Nicolaus upped their price target on Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research note on Friday, July 19th. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $446.45.

Intuitive Surgical Stock Performance

ISRG stock opened at $479.27 on Wednesday. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $493.97. The business’s 50-day moving average is $456.78 and its two-hundred day moving average is $416.47. The company has a market cap of $170.31 billion, a price-to-earnings ratio of 87.26, a P/E/G ratio of 5.43 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the prior year, the company earned $1.18 earnings per share. Intuitive Surgical’s revenue was up 14.5% on a year-over-year basis. Equities analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In other news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares in the company, valued at $1,461,006.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert Desantis sold 239 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $416.60, for a total value of $99,567.40. Following the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,293,799.60. The disclosure for this sale can be found here. Insiders have sold 51,656 shares of company stock valued at $24,700,644 over the last quarter. 0.90% of the stock is currently owned by company insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.